Clinical utility of
Adult
Aged
Aged, 80 and over
Carcinoma, Renal Cell
/ diagnostic imaging
Female
Fluorodeoxyglucose F18
Humans
Kidney Neoplasms
/ diagnostic imaging
Male
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Octreotide
/ analogs & derivatives
Organometallic Compounds
Positron Emission Tomography Computed Tomography
Radiopharmaceuticals
Recurrence
Retrospective Studies
DOTATOC
PET
Recurrence
Renal cell carcinoma
Restaging
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
30
12
2018
accepted:
25
02
2019
pubmed:
9
3
2019
medline:
15
7
2020
entrez:
9
3
2019
Statut:
ppublish
Résumé
Positron emission tomography (PET)/computed tomography (CT) with We analysed 25 consecutive patients who underwent DOTATOC-PET/CT scans after surgery for RCC (23 clear cell, 1 papillary, 1 unclassified). PET/CT findings were reviewed and the detection rate was calculated on a patient and lesion basis. The detectability was compared in patients who also underwent PET/CT scans with Based on the final diagnosis, 76 recurrent or metastatic lesions were confirmed in this population. Of these lesions, 66 lesions in 22 patients were positive by DOTATOC-PET/CT. The patient-based and lesion-based sensitivity was 88% (22/25) and 87% (66/76), respectively. Twelve patients underwent both DOTATOC-PET/CT and FDG-PET/CT. The lesion-based sensitivity of DOTATOC was 74% (20/27), while that of FDG was 59% (16/27). Eight lesions were identified only by DOTATOC, but four lesions from papillary RCC were detected only by FDG. Our data indicate that DOTATOC-PET/CT would be useful for detecting recurrent foci in patients with clear cell RCC. DOTATOC-PET/CT and FDG-PET/CT are considered to have complementary roles.
Identifiants
pubmed: 30847538
doi: 10.1007/s00259-019-04298-4
pii: 10.1007/s00259-019-04298-4
doi:
Substances chimiques
Ga(III)-DOTATOC
0
Organometallic Compounds
0
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1524-1530Subventions
Organisme : Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan
ID : 25461816
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Urology. 2000 Aug 1;56(2):211-5
pubmed: 10925080
Cancer Res. 1992 Nov 1;52(21):6074-8
pubmed: 1394233
J Clin Oncol. 2004 Dec 15;22(24):4991-5004
pubmed: 15611513
Lancet. 2009 Mar 28;373(9669):1119-32
pubmed: 19269025
Eur J Radiol. 2011 Jul;79(1):29-35
pubmed: 20015602
Clin Nucl Med. 2014 Aug;39(8):713-6
pubmed: 24561680
Eur Urol. 2015 May;67(5):913-24
pubmed: 25616710
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1284-94
pubmed: 25975367
Ann Nucl Med. 2015 Dec;29(10):877-82
pubmed: 26286635
Clin Genitourin Cancer. 2016 Feb;14(1):69-75
pubmed: 26337654
J Nucl Med. 2016 Jun;57(6):872-8
pubmed: 26769864
World J Urol. 2017 Feb;35(2):179-188
pubmed: 27277600
Eur Urol. 2016 Dec;70(6):926-937
pubmed: 27363387
Nucl Med Commun. 2017 Feb;38(2):156-163
pubmed: 27824726
J Nucl Med. 2017 May;58(5):756-761
pubmed: 28082438
J Med Imaging Radiat Oncol. 2017 Jun;61(3):372-378
pubmed: 28116853
J Nucl Med. 2017 Sep;58(9):1452-1458
pubmed: 28280220
Clin Nucl Med. 2017 Sep;42(9):700-701
pubmed: 28719449
Clin Nucl Med. 2018 Jan;43(1):44-45
pubmed: 29076916
Clin Nucl Med. 2018 Jan;43(1):e29-e30
pubmed: 29166326
World J Nucl Med. 2018 Jul-Sep;17(3):195-197
pubmed: 30034285
Mol Imaging Biol. 2019 Jun;21(3):567-573
pubmed: 30218388
J Clin Endocrinol Metab. 1995 Oct;80(10):2974-9
pubmed: 7559883